Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Takeda spreads it bets in Huntington’s
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
Roche buys Genmark for Covid-19 tests and more
At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.
The Spac story departs from the script
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
Boston Scientific’s next move
The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
Five Prime's lesson in never giving up
The group’s restructuring, C-suite clearout and refocusing on bemarituzumab is rewarded with a $1.9bn buyout by Amgen.
March medtech merger madness
High asset prices and a need to release the pandemic’s brake on growth force medtechs to splash the cash.
Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
